Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
The purpose of the study is to evaluate the change in cognitive ability and activities of daily living in patients with Alzheimer's disease (AD) as measured by specific evaluations during 18 months of dosing.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
|Official Title:||Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type|
- Cognition and activities of daily living [ Time Frame: 18 mos ] [ Designated as safety issue: No ]
- Global function and behavior [ Time Frame: 18 mos ] [ Designated as safety issue: No ]
|Study Start Date:||February 2005|
|Study Completion Date:||May 2008|
800 mg BID
oral 800 mg BID
Placebo Comparator: 2
Oral BID dosing
This trial is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel group study comparing the safety and efficacy of daily dosing of MPC-7869 to placebo. The study subjects will have the diagnosis of mild dementia of the Alzheimer's type. Subjects may be taking approved medication for Alzheimer's disease provided the dose has been stable for at least 6 months.
The primary objective of the study is to evaluate the change in cognition and activities of daily living.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00105547
Show 133 Study Locations
|Study Director:||Ed Swabb, MD||Myrexis Inc.|